# Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4
Ticker: ESPR
Company: Esperion Therapeutics
Source: Esperion Therapeutics
Published: 2026-05-14 20:30 EST
Original Source URL: https://www.esperion.com
## Summary

ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used

## Article Body
ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used
## Recent Company News
- 2026-05-26 12:00 EST — [Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026](https://biopharmsignal.com/news/ESPR/esperion-presents-new-data-from-clear-outcomes-and-the-clear-path-phase-2-pediatric-study-at-the-european-atherosclerosis-society-congress-2026) — Source: Esperion Therapeutics
- 2026-05-14 20:30 EST — [Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Esperion Therapeutics
- 2026-05-13 12:00 EST — [Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026](https://biopharmsignal.com/news/ESPR/esperion-announces-two-new-analyses-supporting-bempedoic-acid-to-reduce-ldl-c-levels-to-be-presented-at-the-european-atherosclerosis-society-eas-congress-2026) — Source: Esperion Therapeutics
- 2026-05-01 11:00 EST — [Esperion to be Acquired by ARCHIMED](https://biopharmsignal.com/news/ESPR/esperion-to-be-acquired-by-archimed) — Source: Esperion Therapeutics
- 2026-04-23 12:00 EST — [Esperion to Report First Quarter 2026 Financial Results on May 7](https://biopharmsignal.com/news/ESPR/esperion-to-report-first-quarter-2026-financial-results-on-may-7) — Source: Esperion Therapeutics
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)